![conference banner](/images/conference-banner.jpeg)
Abstract
Inhaled drugs have been recognized for their great potential for improved drug delivery, but so far only a fraction of their potential is benefiting clinical practice. Many new promising drug candidates are in development pipelines and some of them are approaching processes of regulatory agencies. Overall, investigation in inhalation drug development is intense. Inhalation administration route provides benefits over other routes of administration, e.g. avoidance of firstpass- metabolism, and convenience for patients in administrations without repeated injections. However, drug development of inhaled substances is complicated and usually development times are longer than ordinary drug development. Additional investigational needs in development of inhaled drugs are dealing with formulation, devices and variability of respiratory function between human subjects. Radiopharmaceuticals provide invaluable tool to explore these issues noninvasively. First, radiopharmaceuticals can be used in vitro for proof of concept studies. Second, they are used to resolve depository issues, as well as to give timeframe for clearance of substances in target organs. Third, radiopharmaceuticals new potential use is focused on extending non-invasive imaging technique towards true pharmacokinetic modelling via calculations of target organ follow-up and exposure. Exposure estimates of a particular drug candidate make safety evaluation feasible early in the drug development. Safety issues can be resolved by investigating exposures of target organs, and depository and absorption issues in airways.
Keywords: Inhaled drugs, firstpass- metabolism, drug development, non-invasive imaging technique, pharmacokinetic modelling
Current Pharmaceutical Design
Title: Role of Radiopharmaceuticals in Development of Inhaled Drugs
Volume: 15 Issue: 9
Author(s): Antti P. Jekunen
Affiliation:
Keywords: Inhaled drugs, firstpass- metabolism, drug development, non-invasive imaging technique, pharmacokinetic modelling
Abstract: Inhaled drugs have been recognized for their great potential for improved drug delivery, but so far only a fraction of their potential is benefiting clinical practice. Many new promising drug candidates are in development pipelines and some of them are approaching processes of regulatory agencies. Overall, investigation in inhalation drug development is intense. Inhalation administration route provides benefits over other routes of administration, e.g. avoidance of firstpass- metabolism, and convenience for patients in administrations without repeated injections. However, drug development of inhaled substances is complicated and usually development times are longer than ordinary drug development. Additional investigational needs in development of inhaled drugs are dealing with formulation, devices and variability of respiratory function between human subjects. Radiopharmaceuticals provide invaluable tool to explore these issues noninvasively. First, radiopharmaceuticals can be used in vitro for proof of concept studies. Second, they are used to resolve depository issues, as well as to give timeframe for clearance of substances in target organs. Third, radiopharmaceuticals new potential use is focused on extending non-invasive imaging technique towards true pharmacokinetic modelling via calculations of target organ follow-up and exposure. Exposure estimates of a particular drug candidate make safety evaluation feasible early in the drug development. Safety issues can be resolved by investigating exposures of target organs, and depository and absorption issues in airways.
Export Options
About this article
Cite this article as:
Jekunen P. Antti, Role of Radiopharmaceuticals in Development of Inhaled Drugs, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787582002
DOI https://dx.doi.org/10.2174/138161209787582002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and Biological Evaluation of Quinoxalin-2(1H)-one Derivatives as EGFR Tyrosine Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Chronic Myelogenous Leukemia
Current Cancer Therapy Reviews The Role of CDK20 Protein in Carcinogenesis
Current Drug Targets Metformin as a Radiation Modifier; Implications to Normal Tissue Protection and Tumor Sensitization
Current Clinical Pharmacology miR-1247 is Correlated with Prognosis of Pancreatic Cancer and Inhibits Cell Proliferation by Targeting Neuropilins
Current Molecular Medicine Interplay Between JSRV, an Oncogenic Retrovirus, and the Pulmonary Epithelium
Current Immunology Reviews (Discontinued) The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Sesbania: A Prospective Candidate to be Excavated for Anticancer Drugs
The Natural Products Journal Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation
Current Medicinal Chemistry Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists
Current Medicinal Chemistry Performance of Green Desymmetrization Methods toward Bioactive Cephalostatin Analogues
Current Medicinal Chemistry Structure and Regulation of the Drug-Metabolizing Enzymes Arylamine N-acetyltransferases
Current Medicinal Chemistry Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Current Pharmaceutical Design Computer-Aided Detection System for the Classification of Non-Small Cell Lung Lesions using SVM
Current Computer-Aided Drug Design Menthol – Pharmacology of an Important Naturally Medicinal “Cool”
Mini-Reviews in Medicinal Chemistry Activatable Molecular Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets